Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Pennsylvania Solvay Pharmaceuticals |
---|---|
Information provided by: | University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT00799617 |
The Testosterone Trials are a multi-center set of trials involving 12 clinical sites geographically distributed across the United States.
The primary specific aims are to test the hypotheses that testosterone treatment of elderly men whose serum testosterone concentrations are unequivocally low - and who have symptoms and objectively measured abnormalities in at least one of five areas that could be due to low testosterone (physical or sexual function, vitality, cognition, and anemia) - will result in more favorable changes in those abnormalities than placebo treatment.
Condition | Intervention | Phase |
---|---|---|
Andropause |
Drug: AndroGel® (testosterone gel) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Randomized, Placebo-Controlled, Double-Blind Study of Five Coordinated Testosterone Treatment Trials in Older Men |
Estimated Enrollment: | 800 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | January 2015 |
Estimated Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Testosterone gel: Active Comparator |
Drug: AndroGel® (testosterone gel)
AndroGel or placebo is applied to the torso, abdomen or upper arms once a day. Subjects will be instructed to wash their hands after application and not to have contact with women or children while the gel is wet. They will also be asked not to bathe or get this area wet for five hours after application. The initial dose of AndroGel will be 7.5 g (containing 75 mg of testosterone) once a day.
|
Placebo gel: Placebo Comparator |
Drug: AndroGel® (testosterone gel)
AndroGel or placebo is applied to the torso, abdomen or upper arms once a day. Subjects will be instructed to wash their hands after application and not to have contact with women or children while the gel is wet. They will also be asked not to bathe or get this area wet for five hours after application. The initial dose of AndroGel will be 7.5 g (containing 75 mg of testosterone) once a day.
|
As men get older, they experience many conditions, often together, that eventually result in the inability to perform many activities of daily living, an increased propensity to fall, and decreased independence. These conditions include mobility disability and low vitality. Elderly men also experience increased anemia, metabolic syndrome, decreased sexual function and memory impairment. These conditions likely have multiple causes, but one cause that could contribute to all of them is a low serum testosterone concentration. When young hypogonadal men are treated with testosterone, they experience improvements in sexual function, muscle mass and strength, bone mineral density, sense of well being, and anemia. However, the benefits of testosterone therapy in older men with age-related decline in testosterone concentration are not known and are the subject of this investigation.
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Use of the following medications within the previous three months:
Contact: Denise Cifelli, MS | 215-573-4534 | cifelli@mail.med.upenn.edu |
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35294 | |
United States, California | |
University of California San Diego | |
La Jolla, California, United States, 92093 | |
University of California at Los Angeles | |
Torrance, California, United States, 90501 | |
United States, Connecticut | |
Yale University | |
New Haven, Connecticut, United States, 06520 | |
United States, Florida | |
University of Florida | |
Gainesville, Florida, United States, 32611 | |
United States, Illinois | |
Northwestern University | |
Chicago, Illinois, United States, 60208 | |
United States, Massachusetts | |
Boston University | |
Boston, Massachusetts, United States, 02215 | |
United States, Minnesota | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 | |
United States, New York | |
Albert Einstein College of Medicine | |
Bronx, New York, United States, 10461 | |
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15261 | |
United States, Texas | |
Baylor College of Medicine | |
Houston, Texas, United States, 76798 | |
United States, Washington | |
University of Washington | |
Seattle, Washington, United States, 98108 |
Principal Investigator: | Peter J Snyder, MD | University of Pennsylvania |
Responsible Party: | University of Pennsylvania ( Peter J. Snyder, MD ) |
Study ID Numbers: | U01 AG030644 |
Study First Received: | November 26, 2008 |
Last Updated: | November 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00799617 |
Health Authority: | United States: Institutional Review Board |
Testosterone Mobility disability Decreased libido |
Age associated memory impairment Low vitality Anemia |
Testosterone Anemia Methyltestosterone Testosterone 17 beta-cypionate |
Anabolic Agents Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Physiological Effects of Drugs |
Hormones, Hormone Substitutes, and Hormone Antagonists Hormones Pharmacologic Actions Androgens |